Investigating the effect of aerobic exercise with and without blood flow restriction in type 2 diabetes

Investigation of SOD2 gene expression and enzyme activity, telomere length in white blood cells, TOS, TAC serum levels following aerobic exercise with and without blood flow restriction in patients with type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230805059032N1

Enrollment

Registered

2024-01-08

Start date

2023-10-23

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: first intervention group: aerobic exercises running on a treadmill with low to moderate intensity with blood flow restriction using the BFR device of Anhoma company

Eligibility

Sex/Gender

Male

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 40 to 60 years History of type 2 diabetes for more than one year Not consuming insulin

Exclusion criteria

Exclusion criteria: Having a heart problem Smoking Not participating regularly in training session Not following health protocols

Design outcomes

Primary

Measure	Time frame
SOD2 gene expression. Timepoint: Before the start of the intervention/16 weeks after the start of the intervention. Method of measurement: SOD2 gene expression with Real Time-PCR method.;SOD2 enemy activity. Timepoint: Before the start of the intervention/16 weeks after the start of the intervention. Method of measurement: Eliza method.;Telomere length. Timepoint: Before the start of the intervention/16 weeks after the start of the intervention. Method of measurement: Telomere length measurement with Real Time-PCR method.;TAC Serum levels. Timepoint: Before the start of the intervention/16 weeks after the start of the intervention. Method of measurement: Eliza method.;TOS Serum levels. Timepoint: Before the start of the intervention/16 weeks after the start of the intervention. Method of measurement: Eliza method.	—

Measure

Time frame

SOD2 gene expression. Timepoint: Before the start of the intervention/16 weeks after the start of the intervention. Method of measurement: SOD2 gene expression with Real Time-PCR method.;SOD2 enemy activity. Timepoint: Before the start of the intervention/16 weeks after the start of the intervention. Method of measurement: Eliza method.;Telomere length. Timepoint: Before the start of the intervention/16 weeks after the start of the intervention. Method of measurement: Telomere length measurement with Real Time-PCR method.;TAC Serum levels. Timepoint: Before the start of the intervention/16 weeks after the start of the intervention. Method of measurement: Eliza method.;TOS Serum levels. Timepoint: Before the start of the intervention/16 weeks after the start of the intervention. Method of measurement: Eliza method.

—

Secondary

Measure	Time frame
FBS. Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Evaluation using a laboratory kit.;HbA1C. Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Evaluation using a laboratory kit.;CBC indices (WBC ,RBC ,HGB,HCT, PLT,..). Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Evaluation using laboratory equipment and techniques.;WHRT. Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Using in body device.;Analysis of body composition (body fat percentage, weight, etc.). Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Using the in body device.;Lower body strength. Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Using a foot dynamometer.;Quality of life questionnaire(SF-36). Timepoint: Before the start of the intervention /16 weeks after the start of the intervention. Method of measurement: Using the quality of life questionnaire (SF-36).	—

Measure

Time frame

FBS. Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Evaluation using a laboratory kit.;HbA1C. Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Evaluation using a laboratory kit.;CBC indices (WBC ,RBC ,HGB,HCT, PLT,..). Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Evaluation using laboratory equipment and techniques.;WHRT. Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Using in body device.;Analysis of body composition (body fat percentage, weight, etc.). Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Using the in body device.;Lower body strength. Timepoint: Before the start of the intervention / 16 weeks after the start of the intervention. Method of measurement: Using a foot dynamometer.;Quality of life questionnaire(SF-36). Timepoint: Before the start of the intervention /16 weeks after the start of the intervention. Method of measurement: Using the quality of life questionnaire (SF-36).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Ansari Rad

University of Sistan and Baluchestan

samirarad22n@gmail.com+98 54 3350 4254

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026